- Home
- CARR vs ALNY Comparison
CARR vs ALNY Comparison
Compare CARR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARR
- ALNY
- Stock Information
- Founded
- CARR 2019
- ALNY 2002
- Country
- CARR United States
- ALNY United States
- Employees
- CARR N/A
- ALNY N/A
- Industry
- CARR Industrial Machinery/Components
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- CARR Industrials
- ALNY Health Care
- Exchange
- CARR Nasdaq
- ALNY Nasdaq
- Market Cap
- CARR 56.3B
- ALNY 59.6B
- IPO Year
- CARR N/A
- ALNY 2004
- Fundamental
- Price
- CARR $59.09
- ALNY $458.59
- Analyst Decision
- CARR Buy
- ALNY Strong Buy
- Analyst Count
- CARR 16
- ALNY 29
- Target Price
- CARR $80.44
- ALNY $448.97
- AVG Volume (30 Days)
- CARR 5.7M
- ALNY 1.0M
- Earning Date
- CARR 10-23-2025
- ALNY 10-30-2025
- Dividend Yield
- CARR 1.50%
- ALNY N/A
- EPS Growth
- CARR 17.18
- ALNY N/A
- EPS
- CARR 4.49
- ALNY N/A
- Revenue
- CARR $22,463,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- CARR $1.92
- ALNY $59.55
- Revenue Next Year
- CARR $5.72
- ALNY $40.90
- P/E Ratio
- CARR $34.63
- ALNY N/A
- Revenue Growth
- CARR 9.02
- ALNY 5.01
- 52 Week Low
- CARR $54.22
- ALNY $205.87
- 52 Week High
- CARR $83.32
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- CARR 36.90
- ALNY 58.80
- Support Level
- CARR $58.70
- ALNY $446.18
- Resistance Level
- CARR $60.77
- ALNY $465.01
- Average True Range (ATR)
- CARR 1.00
- ALNY 11.41
- MACD
- CARR 0.26
- ALNY -2.05
- Stochastic Oscillator
- CARR 28.64
- ALNY 65.04
About CARR Carrier Global Corporation
Carrier Global provides HVAC and refrigeration products and services that serve the global residential, commercial, and transportation markets. The company's HVAC businesses account for approximately 85% of consolidated revenue, with residential and light commercial HVAC and commercial HVAC representing about 60% and 25% of total revenue, respectively. Carrier's refrigeration segment, which accounts for approximately 15% of consolidated revenue, consists of its transportation refrigeration and Sensitech supply chain monitoring products and services.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.